GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biomerica Inc (NAS:BMRA) » Definitions » Earnings per Share (Diluted)

Biomerica (Biomerica) Earnings per Share (Diluted) : $-0.37 (TTM As of Feb. 2024)


View and export this data going back to 1978. Start your Free Trial

What is Biomerica Earnings per Share (Diluted)?

Biomerica's Earnings per Share (Diluted) for the three months ended in Feb. 2024 was $-0.11. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2024 was $-0.37.

Biomerica's EPS (Basic) for the three months ended in Feb. 2024 was $-0.11. Its EPS (Basic) for the trailing twelve months (TTM) ended in Feb. 2024 was $-0.37.

Biomerica's EPS without NRI for the three months ended in Feb. 2024 was $-0.11. Its EPS without NRI for the trailing twelve months (TTM) ended in Feb. 2024 was $-0.37.

During the past 3 years, the average EPS without NRIGrowth Rate was -24.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was -23.00% per year.

During the past 13 years, Biomerica's highest 3-Year average EPS without NRI Growth Rate was 69.50% per year. The lowest was -62.00% per year. And the median was -6.50% per year.


Biomerica Earnings per Share (Diluted) Historical Data

The historical data trend for Biomerica's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomerica Earnings per Share (Diluted) Chart

Biomerica Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.26 -0.26 -0.62 -0.36 -0.50

Biomerica Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.12 -0.10 -0.07 -0.09 -0.11

Competitive Comparison of Biomerica's Earnings per Share (Diluted)

For the Medical Devices subindustry, Biomerica's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomerica's PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biomerica's PE Ratio distribution charts can be found below:

* The bar in red indicates where Biomerica's PE Ratio falls into.



Biomerica Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Biomerica's Earnings Per Share (Diluted) for the fiscal year that ended in May. 2023 is calculated as

Diluted Earnings Per Share (A: May. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-7.14-0)/14.154
=-0.50

Biomerica's Earnings Per Share (Diluted) for the quarter that ended in Feb. 2024 is calculated as

Diluted Earnings Per Share (Q: Feb. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-1.918-0)/16.822
=-0.11

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Biomerica  (NAS:BMRA) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Biomerica Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Biomerica's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomerica (Biomerica) Business Description

Traded in Other Exchanges
N/A
Address
17571 Von Karman Avenue, Irvine, CA, USA, 92614
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Europe market.
Executives
John P. Kenny director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Zacharys Irani director, officer: Cheif Executive Officer 17571 VON KARMAN AVE., IRVINE CA 92614
Gary Lu officer: Chief Financial Officer 12136 AHERN CT, TUSTIN CA 92782
Allen Barbieri director
Catherine Coste director 966 OCHO RIOS DR, DANVILLE CA 94526
David Moatazedi director C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Steven Sloan officer: Chief Financial Officer 114 TERRAPIN, IRVINE CA 92618
Mark A Sirgo director C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607
Francis Cano director 11 ACORN LANE, LOS ALTOS CA 94022
Francis E Capitanio officer: President-diagnostics 1533 MONROVIA AVENUE, NEWPORT BEACH CA 92663
Janet Moore director, 10 percent owner, officer: Secretary 1533 MUNROVIA AVE, NEWPORT BEACH CA 92663
Jane Emerson director 1533 MONROVIA AVE, NEWPORT BEACH CA 92663
William Snider other: Greater than 5% holder 4800 MONTGOMERY LANE, SUITE 230, BETHESDA MD 20814
Broadoak Fund The other: Greater than 5% holder 7201 WISCONSIN AVE. #630, BETHESDA MD 20814
John Roehm director 1533 MONROVIA AVE., NEWPORT BEACH CA 92663